THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., June 13, 2007 -- Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced the presentation of additional data that ...

Please provide your email address to receive an email when new articles are posted on . The etanercept biosimilar, LBEC0101, demonstrated equivalent clinical efficacy and comparable safety profile to ...

A patent fight has already delayed Sandoz' biosimilar version of Amgen's anti-inflammatory blockbuster Enbrel. And now, it looks as if Sandoz will have to wait a little longer for a clear shot at the ...

THOUSAND OAKS, Calif., and RADNOR, Penn., – Results from a study of ENBREL® (etanercept), the only fully human TNF receptor, were presented demonstrating significant inhibition in the progression of ...

Eight months after bowing to FDA pressure to pull the original spot, Amgen has launched a revamped television ad for Enbrel (etanercept) that it says better explains the product’s psoriasis indication ...

Inadequate Initial Response is the Top Reason Why Rheumatologists Move Patients from Simponi and Cimzia, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 7, 2010 /PRNewswire/ ...

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® ...

WASHINGTON — Colorado is pioneering a new way for states to crack down on prescription drug costs. In a first-in-the-nation move, a state board voted to create a payment limit for a widely prescribed ...

U.S. regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world. The Food and Drug ...

An appeals court ruling means biosimilar competition won't affect U.S. Enbrel sales for a long time. Enbrel is a tumor necrosis factor (TNF) inhibitor that earned its first FDA approval all the way ...

On Monday, May 17 th, the U.S. Supreme Court decided not to take up Sandoz’s petition for the Court to review previous lower court decisions on the launch of its biosimilar product. This included a ...